Daratumumab Dosing Frequency and Cost of Care in Multiple Myeloma
Researchers sought to determine the cost and dosing used for daratumumab in treatment of multiple myeloma.
Myeloma
Treatment Duration and Interval of Bortezomib, Lenalidomide for MM Predictive of Skin Rash
A retrospective review sought to better understand the relationship between bortezomib and lenalidomide therapy and treatment-induced skin rash in multiple myeloma.
Patient Similarity Network Can Help Stratify Patients for Multiple Myeloma Treatment
Researchers sought to determine whether a patient similarity network would be able to identify patients based on their gene expression to help apply targeted therapies.
Lifestyle Factors and Quality of Life in Patients With Multiple Myeloma
Researchers discussed the lifestyle factors that may be related to quality of life in patients treated for multiple myeloma.
Daratumumab With Carfilzomib May Offer Cardioprotective Benefit for Multiple Myeloma
Researchers sought to determine whether adding daratumumab to carfilzomib would help prevent cardiovascular adverse events in patients with relapsed/refractory multiple myeloma.
Risk Factors of Catheter-Related Thrombosis in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Researchers sought to determine the risk factors for symptomatic catheter-related thrombosis in patients with multiple myeloma undergoing ASCT.
Qualitative Study Sheds Light on Patient Trust in Shared Decision Making in MM Treatment
Researchers conducted semi-structured interviews with patients with multiple myeloma to determine what factors influence their ability to participate in shared decision making with their clinicians.
Conditioning Regimens Prior to Autologous Transplantation for Multiple Myeloma
A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.
Daratumumab, Lenalidomide, Dexamethasone Shows Survival Benefit for Newly Diagnosed Multiple Myeloma
Researchers sought to determine whether daratumumab with lenalidomide and dexamethasone would improve survival in patients with newly diagnosed multiple myeloma.
STEPS Program After HCT for Multiple Myeloma Is Useful Measure of Patient Status
The physical activity intervention was a feasible and accepted program for patients with MM after hematopoietic cell transplantation, and provided useful information regarding patient recovery.
- Loading...
Loading...
Loading... 
Loading...